Kezar Life Sciences, Inc. (KZR) Amortization of Deferred Charges (2021 - 2025)

Kezar Life Sciences has reported Amortization of Deferred Charges for 5 years, with the latest figure at -$62000.0 in Q4 2025.

• Quarterly Amortization of Deferred Charges fell 193.94% year-over-year to -$62000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $17000.0 (down 95.2% YoY) and the FY2025 annual result came in at $176000.0, down 32.05% from the prior year.
• Amortization of Deferred Charges retreated to -$62000.0 in Q4 2025 per KZR's latest filing, from $37000.0 in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $159000.0 in Q1 2025 and troughed at -$62000.0 in Q4 2025.
• A 5-year average of $57235.3 and a median of $59000.0 in 2023 frame the typical range for Amortization of Deferred Charges.
• The widest YoY moves for Amortization of Deferred Charges: up 148.44% in 2025, down 193.94% in 2025.
• Over 5 years, Amortization of Deferred Charges stood at $91000.0 in 2021, then sank by 40.66% to $54000.0 in 2022, then gained by 9.26% to $59000.0 in 2023, then increased by 11.86% to $66000.0 in 2024, then plunged by 193.94% to -$62000.0 in 2025.
• According to Business Quant data, Amortization of Deferred Charges over the past three periods registered -$62000.0, $37000.0, and $42000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.